Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Janux Therapeutics Inc | NASDAQ:JANX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 48.00 | 19.20 | 50.25 | 9 | 10:05:43 |
| Name and Address of Seller | Title of Securities Sold | Date of Sale | Amount of Securities Sold | Gross Proceeds |
|---|---|---|---|---|
| Avalon Bioventures SPV I L.P. 10955 Vista Sorrento Parkway Suite 200 San Diego � CA � 92130 | Janux Therapeutics, Inc. | 09/06/2024 | 110644 | 4647048.00 |
| Avalon Bioventures SPV I L.P. 10955 Vista Sorrento Parkway Suite 200 San Diego � CA � 92130 | Janux Therapeutics, Inc. | 09/10/2024 | 46604 | 2168465.48 |
| Avalon Bioventures SPV I L.P. 10955 Vista Sorrento Parkway Suite 200 San Diego � CA � 92130 | Janux Therapeutics, Inc. | 09/12/2024 | 161356 | 7583732.00 |
| Avalon Bioventures SPV I L.P. 10955 Vista Sorrento Parkway, Suite 200 San Diego � CA � 92130 | Janux Therapeutics, Inc. | 09/26/2024 | 92200 | 4350513.35 |
| Remarks | Tighe Reardon is a General Partner for Avalon Bioventures SPV I L.P. |
| Date of Notice | 09/27/2024 |
ATTENTION: | |
| The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. | |
| Signature | Tighe Reardon |
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001) | |
1 Year Janux Therapeutics Chart |
1 Month Janux Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
